Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort

Published:2018-09-18 Issue:4 Volume:219 Page:582-589
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Artemchuk Hanna¹,Eriksson Tiina²,Poljak Mario³,Surcel Heljä-Marja⁴⁵,Dillner Joakim¹⁶,Lehtinen Matti¹²,Faust Helena¹

Affiliation:

1. Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

2. University of Tampere, Finland

3. Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Slovenia

4. Faculty of Medicine, University of Oulu, Oulu, Finland

5. European Science Infrastructure Services, Oulu, Finland

6. Clinical Pathology/Cytology, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden

Funder

Swedish Cancer Society

Swedish Foundation for Strategic Research

Karolinska Institutet

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/219/4/582/27636004/jiy545.pdf

Reference36 articles.

1. Human papillomaviruses;IARC Monogr Eval Carcinog Risks Hum,2007

2. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial;Group;BMJ,2010

3. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial;Lehtinen;Lancet Oncol,2012

4. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era;Benard;JAMA Oncol,2017

5. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries;Kjaer;Clin Infect Dis,2018

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ—population-based follow-up of two cluster-randomized trials;Frontiers in Cellular and Infection Microbiology;2024-09-09

2. Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies;Journal of Medical Virology;2024-09

3. Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity;Viruses;2024-08-29

4. Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study;npj Vaccines;2024-08-13

5. The Role of Scientific Research in Human Papillomavirus Vaccine Discussions on Twitter: Social Network Analysis;JMIR Infodemiology;2024-05-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3